Applied Microarrays | GenomeWeb

Applied Microarrays

The companies will jointly offer services and equipment solutions for the development, high-volume manufacture, and launch of multiplexed in vitro diagnostics.

Applied Microarrays and InDevR this week announced a new partnership that will pair AMI's contract array manufacturing resources with InDevR's instrumentation and assay development capabilities.

NEW YORK (GenomeWeb) – InDevR and Applied Microarrays said today that they will work together to offer custom microarrays, instruments, and reagents for multiplexed assays.

Schott, a Jena, Germany-based provider of array surfaces, kits, and reagents, has tapped Applied Microarrays to serve as its distributor in North America.

NEW YORK (GenomeWeb News) – Applied Microarrays earlier this week began distributing Schott Nexterion products in the US and Canada under an agreement forged by the two firms.

This article has been updated from a previous version to include additional comments from AMI.

The bulk of AMI's sales have been derived from printing protein arrays and plates for customers involved in biomarker discovery.

According to the firm's CEO, the majority of the company's sales come from contract manufacturing, while sales of legacy CodeLink bioarray products now account for less than a tenth of AMI's total revenues.

Affy transferred ownership of the 10,000-square-foot Clinical Services Lab to Navigenics earlier this year though an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

Both companies separately last week announced plans to expand the scope of their respective businesses in response to what they said is increased desire from customers to outsource their array production and array-based research projects.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.